How to Choose the Right Pump

Choose the Infusion Method

Subcutaneous or Intravenous

Subcutaneous Immunoglobulin (SCIg) infusion – gives patients flexibility and control of their time. Compared to intravenous immunoglobulin (IVIg) infusions, SCIg has fewer side effects and does not need vein access.^1-4

SCIg	IVIg
Infuse into fat tissue, not vein	Venous access required
Patient self-administered	Healthcare professional required
Daily, weekly, biweekly*¹	Administer every 3-4 weeks
Gradual absorption (24 – 72 hours)¹	Rapid absorption
Fewer peaks and troughs, more consistent Ig levels⁶	High peak and low trough levels⁶
Troughs associated with less infections⁷	Troughs had no relation with infection rates⁷
Pre-medication often not required⁸	Pre-medication commonly required

*Infusion frequency can be tailored to the needs of the individual patients.

Choose the Type of Pump

Electronic or Mechanical

Choosing an infusion device is a very important decision. The two main types of infusion pumps are electronic pumps (or constant flow systems) and mechanical pumps (or constant pressure systems).

	Constant Flow Systems	Constant Pressure Systems (KORU Freedom Systems)
Type of infusion	Electronic	Mechanical
Software	Programmed to a specific flow rate	No programming
Response to saturation	By increasing pressure	By slowing down the infusion to maintain the same safe pressure throughout the infusion

Constant Flow Systems

KORU Freedom Systems

Choose Your Freedom

The Freedom60^® has a simple, ergonomic design that can support large-volume (>30 mL) infusions. The FreedomEDGE^® is smaller, portable and suited for small-volume (≤30 mL) infusions.

	Freedom60®	FreedomEDGE®

Infusion Volume	Large volume infusions Doses over 30mL	Small volume infusions Up to 30mL
Syringe/Dose drawn from vial	BD® 50mL Medline 60mL	BD® 20mL and 30mL
Prefilled syringe (PFS)	Hizentra® 50 mL PFS with adapter	Hizentra® 20 mL PFS

Freedom60®

FreedomEDGE®

Indicated for a Wide Range of Immunoglobulins and Drugs.⁹

The Freedom60^® and FreedomEDGE^® are specifically indicated for the subcutaneous infusion of the following human plasma-derived immunoglobulins when used according to the FDA approved biologic labeling. TheFreedomEDGE® is additionally indicated for the subcutaneous infusion of Empaveli (pegcetacoplan) when used according to the FDA approved labeling.

Refer to the Freedom60^® and FreedomEDGE^® Instructions for Use for a full list of cleared indications for use.

	Freedom60®	FreedomEDGE®
Cutaquig®, Immune Globulin Subcutaneous (Human) 16.5% Solution (manufactured by Octapharma®)
Cuvitru® Immune Globulin Infusion (Human) 20% (manufactured by Takeda®)
Gammagard Liquid®, Immune Globulin Infusion (Human) 10% (manufactured by Takeda®)
Hizentra®, Immune Globulin Subcutaneous (Human) 20% Liquid (manufactured by CSL Behring®)
Hizentra® single-use prefilled syringe	Hizentra® 50 mL PFS compatible with use of Freedom60® PFS Adapter US only	20 mL PFS compatible with FreedomEDGE® Infusion Pump
Xembify®, Immune Globulin Subcutaneous (Human) 20% Liquid (manufactured by Grifols®)
Empaveli® (pegcetacoplan) injection, 1080 mg/20 ml solution (manufactured by Apellis)
Gammanorm® (Human Normal Immunoglobulin, 165 mg/ml Solution)	Outside US only	Outside US only
HyQvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]	Outside US only^†	Outside US only ^†

* Only when used with the Freedom60® Prefilled Syringe Adapter. † Only when used with the Precision™ Flow Rate Controller

Indicated for a Select Range of Antibiotics.⁹

The Freedom Integrated Syringe Infusion System with the Freedom60® and FreedomEDGE^® Syringe Drivers and Precision™ Flow Rate Tubing, are specifically indicated for the intravenous infusion of the following antibiotics when used according to the approved drug product labeling:

	Freedom60®	FreedomEDGE®
Ertapenem
Meropenem
Oxacillin
Tobramycin

Choose a Pump That Works in Harmony With Your Body.

The Freedom™ Infusion System operates at low pressure¹⁰ and uses a constant force spring mechanism to apply constant pressure to the syringe. The constant pressure acts as a safety feature of the device and allows the system to automatically decrease the flow rate if there is an increase in resistance at the patient infusion site.¹⁰ The system will find a dynamic equilibrium between the increasing resistance and the flow rate. This results in fast and safe infusions with minimal infusion site complications.¹¹

For any questions or information, connect with one of our expert healthcare providers.

References

Katzberg H, Lewis RA, Harbo T, Allen JA, Bullock M, Grosse-Kreul D, Smith JB, Bril V. Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy – Neurologist, Nursing and Patient Perspectives. European Neurological Review. 2019; 14(1): 44. doi:10.17925/ENR.2019.14.1.44.
Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112(1):1-7. doi:10.1016/j.clim.2004.02.002
Rojavin MA, Hubsch A, Lawo JP. Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency. J Clin Immunol. 2016;36(3):210-219. doi:10.1007/s10875-016-0243-z
Shrestha P, Karmacharya P, Wang Z, Donato A, Joshi AY. Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies. World Allergy Organ J. 2019;12(10):100068. Published 2019 Oct 9. doi:10.1016/j.waojou.2019.100068
Gustafson R, Gardulf A, Hansen S, et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol. 2008;152(2):274-279. doi:10.1111/j.1365-2249.2008.03620.x
Goyal NA, Karam C, Sheikh KA, Dimachkie MM. Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2021;64(3):243-254. doi:10.1002/mus.27356
Shrestha P, Karmacharya P, Wang Z, Donato A, Joshi AY. Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies. World Allergy Organ J. 2019;12(10):100068. Published 2019 Oct 9. doi:10.1016/j.waojou.2019.100068
Schleiss T, Clarke, DiStefano J, Duruz E, Fadeyi M, Huyhn E, et al., eds. Immunoglobulin Therapy Standards of Practice, 3rd Ed. Immunoglobulin National Society; 2023
K200176 – 510(k) Premarket Notification for FREEDOM Integrated Syringe Infusion System
Allmendinger A, Fischer S. Tissue Resistance during Large-Volume Injections in Subcutaneous Tissue of Minipigs [published correction appears in Pharm Res. 2020 Nov 30;37(12):251. doi: 10.1007/s11095-020-02970-1]. Pharm Res. 2020;37(10):184. Published 2020 Sep 4. doi:10.1007/s11095-020-02906-9
Majapuro-Hirvonen A, Rutland B. Infusing Subcutaneous Immunoglobulins: Comparison of the Constant Flow System (CFS) and Constant Pressure System (CPS). 2024.

Additional Resources